Lupin secures USFDA nod for Rufinamide Oral Suspension
Mumbai, Baltimore: Pharma major, Lupin Limited, has recently announced that the company has received approval for its Rufinamide Oral Suspension, 40 mg/ml, from the United States Food and Drug Administration (USFDA).
The product is a generic equivalent of Banzel Oral Suspension, 40 mg/ml, of Eisai Inc.
Rufinamide Oral Suspension, 40 mg/ml is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.
Rufinamide Oral Suspension, 40 mg/ ml (RLD: Banzel) had estimated annual sales of USD 124.5 million in the U.S. (IQVIA MAT September 2020).
Read also: Lupin gets USFDA nod for generic equivalent of Welchol Tablets
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.